Dual PI3K/HDAC Inhibitor BEBT-908 Exhibits Potent Efficacy as Monotherapy for Primary Central Nervous System Lymphoma

Timing of high dose methotrexate CNS prophylaxis in DLBCL: a multicenter international analysis of 1,384 patients

(2022) Matthew R. Wilson et al.   BLOOD

The PI3K/AKT/mTOR signaling pathway is aberrantly activated in primary central nervous system lymphoma and correlated with a poor prognosis

(2022) Xiaowei Zhang et al.   BMC CANCER

Evidence-based expert consensus on the management of primary central nervous system lymphoma in China

(2022) Tong Chen et al.   Journal of Hematology & Oncology

Recent Progress on Primary Central Nervous System Lymphoma—From Bench to Bedside

(2021) Liang Shao et al.   Frontiers in Oncology

A Dual PI3K/HDAC Inhibitor Induces Immunogenic Ferroptosis to Potentiate Cancer Immune Checkpoint Therapy

(2021) Fushun Fan et al.   CANCER RESEARCH

Management and outcome of primary CNS lymphoma in the modern era

(2020) Caroline Houillier et al.   NEUROLOGY

Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects

(2020) Zhang Xiaowei et al.   CNS & Neurological Disorders-Drug Targets

Targeting phosphatidylinositol 3 kinase-β and -δ for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma

(2020) Neeraj Jain et al.   Blood Advances

Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective ‘proof of concept’ phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)†

(2019) H Ghesquieres et al.   ANNALS OF ONCOLOGY

Stand-alone intrathecal central nervous system (CNS) prophylaxis provide unclear benefit in reducing CNS relapse risk in elderly DLBCL patients treated with R-CHOP and is associated increased infection-related toxicity

(2019) Toby A. Eyre et al.   BRITISH JOURNAL OF HAEMATOLOGY

The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

(2019) Chiara Tarantelli et al.   Cancers

Phase Ib of Copanlisib in Combination with Ibrutinib in Recurrent/Refractory Primary CNS Lymphoma (PCNSL)

(2019) Christian Grommes et al.   BLOOD

The diagnosis and treatment of primary CNS lymphoma—an interdisciplinary challenge

(2018) Louisa von Baumgarten et al.   Deutsches Arzteblatt International

Fatty Acid Synthase induced S6Kinase facilitates USP11-eIF4B complex formation for sustained oncogenic translation in DLBCL

(2018) Bandish Kapadia et al.   Nature Communications

Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: A Systematic review and meta-analysis

(2018) Lu Li et al.   Scientific Reports

Primary CNS Lymphoma

(2017) Christian Grommes et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Temsirolimus for Relapsed/Refractory Primary CNS Lymphoma

(2016) Agnieszka Korfel et al.   JOURNAL OF CLINICAL ONCOLOGY

Primary CNS lymphoma at first relapse/progression: characteristics, management, and outcome of 256 patients from the French LOC network

(2016) Sophie Langner-Lemercier et al.   NEURO-ONCOLOGY

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

(2016) Andrew W. Roberts et al.   NEW ENGLAND JOURNAL OF MEDICINE

PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation

(2016) G. R. Anderson et al.   Science Translational Medicine

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial

(2016) Andrés J M Ferreri et al.   Lancet Haematology

PI3K/mTOR Inhibition Markedly Potentiates HDAC Inhibitor Activity in NHL Cells through BIM- and MCL-1-Dependent Mechanisms In Vitro and In Vivo

(2014) M. Rahmani et al.   CLINICAL CANCER RESEARCH

Systematic identification of signaling pathways with potential to confer anticancer drug resistance

(2014) C. A. Martz et al.   Science Signaling

Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET

(2013) W. Wu et al.   CLINICAL CANCER RESEARCH

Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma

(2011) M Deckert et al.   LEUKEMIA

Myc-Mediated Transcriptional Repression by Recruitment of Histone Deacetylase

(2008) J. F. Kurland et al.   CANCER RESEARCH